Recombinant factor VII a analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa-Reference-Cited by-同舟云学术

Recombinant factor VII a analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

Published:2014-07-16 Issue:8 Volume:12 Page:1244-1253
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Lentz S. R.¹,Ehrenforth S.²,Abdul Karim F.³,Matsushita T.⁴,Weldingh K. N.⁵,Windyga J.⁶,Mahlangu J. N.⁷,

Affiliation:

1. Department of Internal Medicine Carver College of Medicine University of Iowa Iowa City IA USA

2. Novo Nordisk A/S Søborg Denmark

3. Haemophilia Center National Blood Centre Kuala Lumpur Malaysia

4. Department of Transfusion Medicine Nagoya University Hospital Nagoya Japan

5. Novo Nordisk A/S Maalov Denmark

6. Department of Disorders of Hemostasis and Internal Medicine Institute of Hematology and Transfusion Medicine Warsaw Poland

7. Haemophilia Comprehensive Care Centre Faculty of Health Sciences University of the Witwatersrand and National Health Laboratory Service Johannesburg South Africa

Funder

Novo Nordisk

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.12634

Reference28 articles.

1. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

2. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors

3. Single 270 μg kg−1-dose rFVIIa vs. standard 90 μg kg−1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison